Home › Compare › AVRO vs O

AVRO vs O: Dividend Comparison 2026

AVRO yields 142.86% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVRO wins by $19.52M in total portfolio value
10 years
AVRO
AVRO
● Live price
142.86%
Share price
$1.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.55M
Annual income
$8,225,014.26
Full AVRO calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — AVRO vs O

📍 AVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVROO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVRO + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AVRO pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVRO
Annual income on $10K today (after 15% tax)
$12,142.86/yr
After 10yr DRIP, annual income (after tax)
$6,991,262.12/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, AVRO beats the other by $6,986,924.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVRO + O for your $10,000?

AVRO: 50%O: 50%
100% O50/50100% AVRO
Portfolio after 10yr
$9.79M
Annual income
$4,115,058.50/yr
Blended yield
42.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

AVRO
No analyst data
Altman Z
-0.7
Piotroski
4/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVRO buys
0
O buys
0
No recent congressional trades found for AVRO or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVROO
Forward yield142.86% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$19.55M$34.2K ✓
Annual income after 10y$8,225,014.26 ✓$5,102.74
Total dividends collected$18.03M$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: AVRO vs O ($10,000, DRIP)

YearAVRO PortfolioAVRO Income/yrO PortfolioO Income/yrGap
1← crossover$24,986$14,285.71$10,818$608.16+$14.2K → AVRO
2$60,093$33,358.76$11,787$741.68+$48.3K → AVRO
3$139,283$74,982.82$12,946$911.00+$126.3K → AVRO
4$311,456$162,423.26$14,345$1,127.94+$297.1K → AVRO
5$672,698$339,440.31$16,056$1,409.05+$656.6K → AVRO
6$1,404,965$685,177.81$18,171$1,777.83+$1.39M → AVRO
7$2,840,723$1,337,410.52$20,820$2,268.21+$2.82M → AVRO
8$5,566,801$2,527,227.75$24,188$2,929.90+$5.54M → AVRO
9$10,584,947$4,628,469.98$28,533$3,837.11+$10.56M → AVRO
10$19,550,908$8,225,014.26$34,235$5,102.74+$19.52M → AVRO

AVRO vs O: Complete Analysis 2026

AVRO — Stock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full AVRO Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this AVRO vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVRO vs SCHDAVRO vs JEPIAVRO vs KOAVRO vs MAINAVRO vs STAGAVRO vs ADCAVRO vs NNNAVRO vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.